-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TDAfQC45wYS8dOsva8niFLliCg0ZEv/cnlwuUC/HRvc2vZ4UtLomyhg2kk+gyA8q 2/AvR7yyYxk14JIjNalMqg== 0000882377-03-001391.txt : 20030908 0000882377-03-001391.hdr.sgml : 20030908 20030908152214 ACCESSION NUMBER: 0000882377-03-001391 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030908 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CALYPTE BIOMEDICAL CORP CENTRAL INDEX KEY: 0000899426 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 061226727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-50235 FILM NUMBER: 03885985 BUSINESS ADDRESS: STREET 1: 1265 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502- BUSINESS PHONE: 5107495100 MAIL ADDRESS: STREET 1: 1265 HARBOR BAY PKWY CITY: ALAMEDA STATE: CA ZIP: 94502 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MARR TECHNOLOGIES BV CENTRAL INDEX KEY: 0001262853 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NEDTHERLANDS STATE: P7 ZIP: 00000 BUSINESS PHONE: 0110031206625501 MAIL ADDRESS: STREET 1: STRAWINSKYLAAN 1431 STREET 2: 1077XX CITY: AMSTERDAM THE NETHERLANDS STATE: P7 ZIP: 00000 SC 13D 1 d169560.txt CALYPTE BIOMEDICAL CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CALYPTE BIOMEDICAL CORPORATION (Name of Issuer) COMMON STOCK $.03 PAR VALUE (Title of Class of Securities) 131722100 (CUSIP Number) WALTER G. VAN DORN, JR., ESQ. THACHER PROFFITT & WOOD 2 WORLD FINANCIAL CENTER, NEW YORK, NEW YORK 10281 (212) 912-7400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 21, 2003 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of Rule13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 5 Pages) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act. but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP NO. 131722100 SCHEDULE 13D PAGE 2 OF 5 PAGES 1 NAME OF REPORTING PERSON: Marr Technologies BV S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (voluntary): ______________________________________________________________ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (see instructions) (b) [ ] ________________________________________________________________________________ 3 SEC USE ONLY ________________________________________________________________________________ 4 SOURCE OF FUNDS (see instructions) WC ________________________________________________________________________________ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] ________________________________________________________________________________ 6 CITIZENSHIP OR PLACE OF ORGANIZATION The Netherlands ________________________________________________________________________________ NUMBER OF 7 SOLE VOTING POWER SHARES 12,433,333 (See Item 5) BENEFICIALLY ___________________________ OWNED BY 8 SHARED VOTING POWER EACH 0 REPORTING ___________________________ PERSON 9 SOLE DISPOSITIVE POWER WITH 12,433,333 (See Item 5) ___________________________ 10 SHARED DISPOSITIVE POWER 0 ________________________________________________________________________________ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,433,333 ________________________________________________________________________________ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [ ] ________________________________________________________________________________ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 21.4% (See Item 5) ________________________________________________________________________________ 14 TYPE OF REPORTING PERSON (see instructions) CO CUSIP NO. 131722100 SCHEDULE 13D PAGE 3 OF 5 PAGES Item 1. Security and Issuer. This Schedule 13D relates to common stock, $0.03 par value (the "Common Stock") of Calypte Biomedical Corporation, a Delaware corporation (the "Company"). The Company's principal executive offices are located at 1265 Harbor Bay Parkway, Alameda, California 94502. Item 2. Identity and Background This Schedule 13D is being filed by Marr Technologies BV ("MTBV"), a Limited Company incorporated in The Netherlands. MTBV engages in the technology business and investment in the technology sector. The address of its principal business and its principal office is Strawinskylaan 1431, 1077XX, Amsterdam, The Netherlands. MTBV has never been convicted in a criminal proceeding nor has it ever been a party to a civil or criminal proceeding before any administrative or judicial body resulting in a judgment, decree or final order to which it is or was subject. Item 3. Source and Amount of Funds or Other Consideration MTBV purchased 12,433,333 shares of common stock of the Company over a period beginning on July 29, 2003 and ending on August 21, 2003. MTBV spent $3,102,340 in making such purchases. MTBV funded such purchases from its working capital. Item 4. Purpose of Transaction MTBV purchased its shares of common stock of the Company for investment purposes. MTBV may make further purchases of shares of the Company's common stock in the future. Except as set forth in this Item 4, MTBV does not have any plans or proposals which relate to or which would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. Item 5. Interest in Securities of the Issuer MTBV has sole voting and dispositive power with respect to 12,433,333 shares, or approximately 21.4% of the 58,066,483 shares of common stock of the Company outstanding. The following table sets forth a description of the transactions effected by MTBV in the class of securities reported herein in the past 60 days. CUSIP NO. 131722100 SCHEDULE 13D PAGE 4 OF 5 PAGES Date Number of Shares Price Per Share - ---- ---------------- --------------- 7/29/03 8,333,333 $0.30 8/14/03 800,000 $0.1506 8/15/03 800,000 $0.1414 8/17/03 1,300,000 $0.145 8/21/03 1,200,000 $0.1502 Such shares were purchased in a combination of privately negotiated transactions and open market transactions effected on the Over the Counter Bulletin Board. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer None. Item 7. Material to be Filed As Exhibits. None. CUSIP NO. 131722100 SCHEDULE 13D PAGE 5 OF 5 PAGES SIGNATURES After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true and complete. Dated: August 29, 2003 MARR TECHNOLOGIES BV By: /s/ Christian Strik ----------------------- Name: Christian Strik Title: Attorney -----END PRIVACY-ENHANCED MESSAGE-----